TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
41 hedge funds and large institutions have $7.84M invested in TFF Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 13 closing their positions.
645% more call options, than puts
Call options by funds: $149K | Put options by funds: $20K
9% less funds holding
Funds holding: 45 → 41 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
54% less capital invested
Capital invested by funds: $17M → $7.84M (-$9.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.3M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.84M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$812K |
| 4 |
Millennium Management
New York
|
+$361K |
| 5 |
Renaissance Technologies
New York
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gagnon Securities
New York
|
-$422K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$193K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$162K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$113K |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$83K |
TFFP Hedge Fund Activity: Q4 2022 in Review
41 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q4 2022, worth a combined $7.84M — down 54% from $17M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TFFP and 9 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.3M. The largest seller was Gagnon Securities, cutting an estimated $422K.
- 41 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q4 2022, down from 45 in Q3 2022.
- Funds reported $7.84M of TFF Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 54% quarter-over-quarter.
- 9 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -4 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was AIGH Capital Management, an estimated $3.3M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Gagnon Securities, an estimated $422K sold.
Based on aggregated 13F filings for Q4 2022.